Glyceraldehyde-3-phosphate dehydrogenases (GAPHD) is the only glycolytic enzyme that has been identified to predict the overall survival (OS) of patients with DLBCL treated with R-CHOP, and this suggests that high levels of GAPDH can resist the effects of mitochondrial inhibition [28]. Here, GAPDH is linked to diffuse large B-cell lymphoma.